First Time Loading...

Chinook Therapeutics Inc
NASDAQ:KDNY

Watchlist Manager
Chinook Therapeutics Inc Logo
Chinook Therapeutics Inc
NASDAQ:KDNY
Watchlist
Price: 40.39 USD Market Closed
Updated: Apr 27, 2024

Intrinsic Value

KDNY's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. [ Read More ]

The intrinsic value of one KDNY stock under the Base Case scenario is 17.22 USD. Compared to the current market price of 40.39 USD, Chinook Therapeutics Inc is Overvalued by 57%.

Key Points:
KDNY Intrinsic Value
Base Case
17.22 USD
Overvaluation 57%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Chinook Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling KDNY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Chinook Therapeutics Inc

Provide an overview of the primary business activities
of Chinook Therapeutics Inc.

What unique competitive advantages
does Chinook Therapeutics Inc hold over its rivals?

What risks and challenges
does Chinook Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Chinook Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Chinook Therapeutics Inc.

Provide P/S
for Chinook Therapeutics Inc.

Provide P/E
for Chinook Therapeutics Inc.

Provide P/OCF
for Chinook Therapeutics Inc.

Provide P/FCFE
for Chinook Therapeutics Inc.

Provide P/B
for Chinook Therapeutics Inc.

Provide EV/S
for Chinook Therapeutics Inc.

Provide EV/GP
for Chinook Therapeutics Inc.

Provide EV/EBITDA
for Chinook Therapeutics Inc.

Provide EV/EBIT
for Chinook Therapeutics Inc.

Provide EV/OCF
for Chinook Therapeutics Inc.

Provide EV/FCFF
for Chinook Therapeutics Inc.

Provide EV/IC
for Chinook Therapeutics Inc.

Show me price targets
for Chinook Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Chinook Therapeutics Inc?

How accurate were the past Revenue estimates
for Chinook Therapeutics Inc?

What are the Net Income projections
for Chinook Therapeutics Inc?

How accurate were the past Net Income estimates
for Chinook Therapeutics Inc?

What are the EPS projections
for Chinook Therapeutics Inc?

How accurate were the past EPS estimates
for Chinook Therapeutics Inc?

What are the EBIT projections
for Chinook Therapeutics Inc?

How accurate were the past EBIT estimates
for Chinook Therapeutics Inc?

Compare the revenue forecasts
for Chinook Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Chinook Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Chinook Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Chinook Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Chinook Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Chinook Therapeutics Inc with its peers.

Analyze the financial leverage
of Chinook Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Chinook Therapeutics Inc.

Provide ROE
for Chinook Therapeutics Inc.

Provide ROA
for Chinook Therapeutics Inc.

Provide ROIC
for Chinook Therapeutics Inc.

Provide ROCE
for Chinook Therapeutics Inc.

Provide Gross Margin
for Chinook Therapeutics Inc.

Provide Operating Margin
for Chinook Therapeutics Inc.

Provide Net Margin
for Chinook Therapeutics Inc.

Provide FCF Margin
for Chinook Therapeutics Inc.

Show all solvency ratios
for Chinook Therapeutics Inc.

Provide D/E Ratio
for Chinook Therapeutics Inc.

Provide D/A Ratio
for Chinook Therapeutics Inc.

Provide Interest Coverage Ratio
for Chinook Therapeutics Inc.

Provide Altman Z-Score Ratio
for Chinook Therapeutics Inc.

Provide Quick Ratio
for Chinook Therapeutics Inc.

Provide Current Ratio
for Chinook Therapeutics Inc.

Provide Cash Ratio
for Chinook Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Chinook Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Chinook Therapeutics Inc?

What is the current Free Cash Flow
of Chinook Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Chinook Therapeutics Inc.

Financials

Balance Sheet Decomposition
Chinook Therapeutics Inc

Current Assets 305.4m
Cash & Short-Term Investments 297.2m
Receivables 3.1m
Other Current Assets 5.2m
Non-Current Assets 183.4m
Long-Term Investments 48m
PP&E 59.1m
Intangibles 60.1m
Other Non-Current Assets 16.2m
Current Liabilities 52.5m
Accounts Payable 16.4m
Accrued Liabilities 33.6m
Other Current Liabilities 2.5m
Non-Current Liabilities 79.3m
Other Non-Current Liabilities 79.3m
Efficiency

Earnings Waterfall
Chinook Therapeutics Inc

Revenue
5.8m USD
Operating Expenses
-257.5m USD
Operating Income
-251.6m USD
Other Expenses
6m USD
Net Income
-245.7m USD

Free Cash Flow Analysis
Chinook Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

KDNY Profitability Score
Profitability Due Diligence

Chinook Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROE is Increasing
Negative 1-Year Revenue Growth
Declining ROIC
15/100
Profitability
Score

Chinook Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

KDNY Solvency Score
Solvency Due Diligence

Chinook Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
80/100
Solvency
Score

Chinook Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KDNY Price Targets Summary
Chinook Therapeutics Inc

Wall Street analysts forecast KDNY stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KDNY is 40 USD .

Lowest
Price Target
Not Available
Average
Price Target
40 USD
1% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

KDNY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

KDNY Price
Chinook Therapeutics Inc

1M 1M
-
6M 6M
-
1Y 1Y
+109%
3Y 3Y
+163%
5Y 5Y
+107%
10Y 10Y
-81%
Annual Price Range
40.39
52w Low
18.66
52w High
40.39
Price Metrics
Average Annual Return 35.15%
Standard Deviation of Annual Returns 123.1%
Max Drawdown -79%
Shares Statistics
Market Capitalization 2.7B USD
Shares Outstanding 67 049 500
Percentage of Shares Shorted 4.97%

KDNY Return Decomposition
Main factors of price return

What is price return decomposition?

KDNY News

Last Important Events
Chinook Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Chinook Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Chinook Therapeutics Inc Logo
Chinook Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.7B USD

Dividend Yield

0%

Description

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company is headquartered in Seattle, Washington and currently employs 138 full-time employees. The company went IPO on 2015-04-15. The firm is focused on discovering, developing and commercializing medicines for kidney diseases. Its lead product candidate is atrasentan, which is a selective endothelin A receptor antagonist that is developed for the treatment of proteinuric glomerular diseases. The Company’s second product candidate, BION-1301, is an investigational humanized IgG4 monoclonal antibody that blocks APRIL, a soluble factor that is implicated in IgAN and other indications, from binding to its receptors. Its third clinical development candidate is CHK-336, a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which is developed for the treatment of primary hyperoxaluria (PH), as well as secondary hyperoxaluria and idiopathic kidney stone formation. The company is conducting a Phase I/II clinical trial of BION-1301.

Contact

WASHINGTON
Seattle
400 Fairview Avenue North, Suite 900
+12064857051.0
https://www.chinooktx.com/

IPO

2015-04-15

Employees

138

Officers

Pres, CEO & Director
Mr. Eric L. Dobmeier J.D.
Chief Operating Officer
Mr. Tom Frohlich
Chief Scientific Officer
Mr. Andrew James King D.V.M., Ph.D.
Chief Financial Officer
Mr. Eric H. Bjerkholt M.B.A.
VP of Investor Relations & Corp. Communications
Ms. Noopur Batsha Liffick
Sr. VP & Gen. Counsel
Mr. Kirk D. Schumacher J.D.
Show More
VP of HR
Ms. Jodi Jamieson
Exec. Officer
Dr. Alan Glicklich M.D.
Sr. VP of CMC & Technical Operations
Ms. Delphine Imbert Ph.D.
Sr. VP of Product Devel. & Strategy
Dr. Charlotte Jones-Burton M.D., M.S.
Show Less

See Also

Discover More
What is the Intrinsic Value of one KDNY stock?

The intrinsic value of one KDNY stock under the Base Case scenario is 17.22 USD.

Is KDNY stock undervalued or overvalued?

Compared to the current market price of 40.39 USD, Chinook Therapeutics Inc is Overvalued by 57%.